Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.

Knight Therapeutics Inc., (TSX: GUD) ('Knight') a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory ...

The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), which is a menin inhibitor, for the treatment ...

Let us honor Gail Zeamer by ensuring that when a woman is told her mammogram might not be enough, she does not have to ...

Combinations of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) are the accepted ...

Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...

To understand treatment patterns and preferences, a series of expert-led Case-Based Roundtable events were conducted over the ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A ...

The latest update is out from Syndax Pharmaceuticals ( (SNDX) ).

Why are lobular breast cancers found at later stages? What are the biological hallmarks of this disease? Are there ways to ...